NCT06038461View on ClinicalTrials.gov

An Open, Single-center Clinical Study of Surufatinib Combined With Temozolomide and S-1 in the First-line Treatment of Advanced Neuroendocrine Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 15, 2023

Primary Completion Date

September 15, 2026

Study Completion Date

September 15, 2026

Conditions
Neuroendocrine Tumors
Interventions
DRUG

Surufatinib Combined With Temozolomide and S-1

"Phase I:~Surufatinib: 250mg, QD, PO, Q3W; Temozolomide: 200-300mg, d10-d14, QD, PO, Q3W; S-1: 40-60mg, d1-d14, BID, PO, Q3W.~Phase II:~Surufatinib, Temozolomide and S-1：RP2D"

Trial Locations (1)

100021

RECRUITING

Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors
lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER